



Managing Stem Cell Shipping Effectively with IRT

Setting the Scene

Clinical trials involving stem cell therapies present added complexity in regard to treatment logistics: the treatment is collected from a participant or donor, shipped to a manufacturing site, modified, and then shipped to the treatment facility for participant administration.


Effective treatment requires cell preservation, which is often done by cryopreservation. If the cryopreservation is not well-managed or is suboptimal, cell viability and the therapy production process can be negatively impacted. Additionally, the efficacy of the therapy may be compromised due to non-ideal frozen storage conditions.¹

Understanding the Challenge

This was a double-blind trial, involving participants with a surgery date at least 2 weeks post-randomization, to allow sufficient time for stem cell production and shipment.

The stem cell expiration was within 48 hours, with a shipment date within 48 hours of surgery. Each kit had a specific expiry date, which is unusual for an IRT.

Additionally, we were dealing with a single manufacturing facility located in Spain, and covering:




1. Hunt C, J: Technical Considerations in the Freezing, Low-Temperature Storage and Thawing of Stem Cells for Cellular Therapies. Transfus Med Hemother 2019;46:134-150. doi: 10.1159/000497289



The Solution

Perceptive delivered an effective IRT solution that enabled cell preservation during this challenging trial.



- 1. Site randomizes the participant and enters the expected surgery date and time.
- 2. IRT sends participant number, surgery date, treatment group and kit number to manufacturing facility.
- 3. Depot confirms kit dispatch in IRT, entering the latest arrival date and time, to acount for kit expiry date.
- 4. Upon shipment arrival, site enters actual date and time of arrival.
- 5. Site enters the actual surgery date and time
- IRT controls in place to manage kit expiry.

Key Highlights

Strict controls set in IRT to allow sufficient time between randomization and surgery.

IRT accounted for potential differences between depot and site local times to ensure expiry controls did not fail.

IRT capped the number of participants enrolled in the same region over time to account for manufacturing limits.

Caps were editable by study team for simplicity and improved reaction time to unforseen situations.

In-depth training provided to site users to reduce risk of delaying stem cell production and shipment.